Who is sponsoring NCT02603705?

NCT02603705 is sponsored by Egalet Ltd.

What drugs are being tested in NCT02603705?

Interventions in NCT02603705: Oxycodone extended-release.

What condition does NCT02603705 study?

NCT02603705 studies Moderate-to-severe Chronic Noncancer Pain.

Is NCT02603705 still recruiting?

NCT02603705 is currently completed. Last updated 5 March 2018.

Last reviewed 2018-03-05 · How we verify

NCT02603705

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain

Completed Phase 3 Last updated 5 March 2018

What this trial tests

Phase 3 trial testing Oxycodone extended-release in Moderate-to-severe Chronic Noncancer Pain in 281 participants. Completed in 15 June 2017.

Timeline

7 March 2016

Primary endpoint
15 June 2017

15 June 2017

Quick facts

Lead sponsor	Egalet Ltd
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	281
Start date	7 March 2016
Primary completion	15 June 2017
Estimated completion	15 June 2017
Sites	39 locations across United States

Drugs / interventions tested

Oxycodone extended-release

Conditions studied

Moderate-to-severe Chronic Noncancer Pain — all drugs for Moderate-to-severe Chronic Noncancer Pain →

Sponsor

Egalet Ltd — full company profile →

Who can join

Adults 18 to 75, any sex, with Moderate-to-severe Chronic Noncancer Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and tolerability of Egalet-002 in opioid-experienced patients with moderate-to-severe chronic noncancer pain.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Oxycodone extended-release

Trials testing the same drug.

NCT02454712 — Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101) · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02603705 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Egalet Ltd
Last refreshed: 5 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02603705.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing